TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Wound Area Change (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective response to MDMA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first confirmed occurrence of Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder's proportion difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who received oral step-down therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Benzodiazepine dose at 6 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Device Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration (Cavg) of Posaconazole Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Concentration (Cmin) of Posaconazole Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Posaconazole Tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant change in VJI distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: pleth variability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ventilatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Meeting Efficacy Success Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of mobilizing CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean systolic blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in average NRS (Brief Pain Inventory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative VAS/NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intent to become screened for CRC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent difference in leiomyoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: C Difficile Infection (CDI) Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immune response to F1 and V antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of skin hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean time at which the highest drug concentration occurs (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects participating in fasting blood draw
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC for nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPID for sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between PA and physician ratings of bowel cleanliness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vo2 kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ovarian cancer incidence attributable to mutations in known predisposing genes
Endpoint domain: Mortality/survival
Primary endpoint: Risk associated with predisposing mutations
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal Changes in Clinical Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vision-targeted health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinician/Investigator's Global Assessment of Therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject's Global Assessment of Therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Protein intake relative to requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes on Walking Index for Spinal Cord Injury II (WISCI-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on ASIA Impairment Scale (AIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume and Number of Muscle Fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: outcome
Endpoint domain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Leuprorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the plasma drug Concentration-time curve to last measurement (AUClast) of Leuprorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t1/2) Luteinizing Hormone (LH) of Leuprorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with unexpected Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients with Abnormal IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients with Positive Ischemia on Stress Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in symptoms of Generalized Anxiety Disorder (GAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion achieving remission on HRSD-24
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long Term Monocular Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long Term Binocular Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defocus Curve Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Remaining in Remission at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: potency function
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Kisspeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax - Peak Plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Motor score - Off medication/On DBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study related adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Time to home discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: response rate of CIDP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Summated compound motor action potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: heart rate under exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in step symmetry during 20m walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hierarchic Dementia Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the plasma concentration-time curve to the end of the dosing period [AUC(tau)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of global reverse cholesterol transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants logging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients who reduced eating duration by 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occult hepatitis B virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of overt hepatitis B virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptance and Action Questionnaire-II (AAQ-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC(0-tn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of ipilimumab in combination with dasatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Dose finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose Limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Consumer Quality index (CQ-index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in 25(OH) vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in frequency of days with moderate or severe migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bishop score greater than or equal to 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Tracheostomy weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total oral feeding recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to decannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 24h ambulant blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NRS Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of standard alcohol units consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: measure of tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac MRI Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of ultrasonography examinations validating correct NGT insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of MILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal torque of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal torque of ankle plantar flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Limb Symmetry Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stable intraperitoneal osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrafiltered volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional synthesis rate of collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Root coverage measure (in millimeter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Target Plaque Severity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bronchial angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Infra-Red radiation emitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Bleeding Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 17-Item Hamilton Rating Scale for Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of AC2 in detecting Neisseria gonorrhoeae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of AC2 in detecting Neisseria gonorrhoeae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity of AC2 in detecting Chlamydia trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of AC2 in detecting Chlamydia trachomatis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dropout due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of postoperative vaginal irritation symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Buccal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child intelligence at 33 months of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postanesthesia Emergence Agitation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Additional Uterotonic Medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in patient´s function from baseline to 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Identification of patients unlikely to respond to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring early endoscopic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cure of VAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Steady state pharmacokinetics of raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state pharmacokinetics of etravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state pharmacokinetics of maraviroc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function measurements (FEV1 and FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Death or transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive learning measurement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression of Temporal Summation of Second Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability Score for the Last Dose of the Suspension on Day 3 for Subjects < 5 Years
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in clinical improvement of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUClast) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of grade≥2 radiation pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in leg glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in whole body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Achieving Complete or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid-Femoral Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance regarding the mutation of RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ucb L057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net acid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pupil Diameter Returning to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related death
Endpoint domain: Mortality/survival
Primary endpoint: Cortical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Standard Uptake Value Ratios (SUVr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum light intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychologic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morpho-functional left ventricle characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined AUC of Selected Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Combined AUC of Selected Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Combined AUC of Selected Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in COPD Assessment Test (CAT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cosmetic outcome after wound healing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose (MTD) of ABBV-368
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 dose (RPTD) for ABBV-368
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Brachial Artery Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ETDRS Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with anti-thyroid drug related agranulocytosis
Endpoint domain: Adverse events/effects
Primary endpoint: Distance traveled in six minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hypoxic Burden (HB) Log Transformed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hypoxic Burden (HB) Raw Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoresponse after first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of cytomegalovirus (CMV) infection or disease
Endpoint domain: Adverse events/effects